Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 5 of 5 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/26/19
End: 03/28/22
Due: 03/28/23
Phase: N/A
Priority: Normal
Start: 11/14/23
End: 11/30/27
Due: 11/30/28
Phase: N/A
Priority: Normal
Start: 07/09/24
End: 07/31/27
Due: 07/31/28
Phase: N/A
Priority: Normal
Start: 04/28/21
End: 11/28/22
Due: 11/28/23
Phase: N/A
Priority: Normal
Start: 01/24/22
End: 05/19/22
Due: 05/19/23
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| First in Human Study: LIS1, an Induction Treatment in Kidney Transplanted Patients | NCT04431219 | Xenothera SAS | user2@example.com | None | 2019-11-26 | 2022-03-28 | 2023-03-28 | - | - | 2025-07-14 |
| FIH XON7 in Advanced/Metastatic Solid Tumors | NCT06154291 | Xenothera SAS | user2@example.com | None | 2023-11-14 | 2027-11-30 | 2028-11-30 | - | - | 2025-07-14 |
| Polyspecific Antibodies in Lymphoproliferative T-cell Disorders | NCT06495723 | Xenothera SAS | user2@example.com | None | 2024-07-09 | 2027-07-31 | 2028-07-31 | - | - | 2025-07-14 |
| Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19 | NCT04928430 | Xenothera SAS | user2@example.com | None | 2021-04-28 | 2022-11-28 | 2023-11-28 | - | - | 2025-07-14 |
| A First-in-Human Study With XAB05 in Healthy Subjects | NCT05307406 | Xenothera SAS | user2@example.com | None | 2022-01-24 | 2022-05-19 | 2023-05-19 | - | - | 2025-07-14 |